Year: 2017
Type: dissertation
Abstract: A critical problem in the clinical management of prostate cancer is that it shows high \nintra- and inter-tumoural heterogeneity. As a result, accurate prediction of individual \ncancer behaviour is not achievable at the time of diagnosis, leading to substantial \novertreatment. It remains an enigma that, in contrast to other cancers, no molecular \nbiomarkers which define robust subtypes of prostate cancer with distinct clinical \noutcomes have been discovered. \nIn the first part of this study, using data from exon microarrays, we developed a novel \nmethod that can identify transcriptional alterations within genes. The alterations might \nbe the result of chromosomal rearrangements, such as translocations, and deletions, or \nof other abnormalities, such as read-through transcription and alternative transcriptional \ninitiation sites. Using data from two independent datasets we identify several candidate \nalterations that are constantly correlated with the biochemical failure or that are linked \nto the development of metastasis. \nIn the second part of the study we illustrate the application of an unsupervised \nBayesian procedure, which identifies a subtype of the disease in five prostate cancer \ntranscriptome datasets. Cancers assigned to this subtype (designated DESNT cancers) \nare characterized by low expression of a core set of 45 genes. For the four datasets \nwith linked PSA failure data following prostatectomy, patients with DESNT cancer \nexhibited poor outcome relative to other patients (p = 2.65 ・ 10−5, p = 4.28 ・ 10−5, p = \n2.98 ・ 10−8 and p = 1.22 ・ 10−3). The DESNT cancers are not linked with the presence \nof any particular class of genetic mutation, including ETS gene status. However, the \nmethylation analysis reveals a possible role of epigenetic changes in the generation of \nthe DESNT subtype. Our results demonstrate the existence of a novel poor prognosis \ncategory of human prostate cancer and will assist in the targeting of therapy, helping \navoid treatment-associated morbidity in men with indolent disease. \n
Author: Luca Bogdan-Alexandru
Institution: University of East Anglia
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Keywords: prostate cancer, biomarkers, tumor heterogeneity, gene expression changes, chromosomal rearrangements, translocation, read-through transcription, biochemical recurrence, metastasis, prostate cancer subtypes, prognosis, epigenetic methylation, prostate-specific antigen, overtreatment, exon microarrays
Open Access status: green
OpenAlex ID: W2724381099
